Powerful buyers, the end of limits on generic Revlimid and fast-fading launches are squeezing Indian drugmakers’ US business. Complex products offer a way to protect pricing power, but developing them requires higher R&D spending and years of investment before they can replace lost revenue. Source link Post navigation Iran planning ‘dirty bomb’, chemical weapon attack on Trump officials in Washington, warns US intelligence: Report Andhra gas leak: ONGC well incident triggers safety alert in Konaseema district